866-997-4948(US-Canada Toll Free)

Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide 2017

Published By :

MarketLine

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 113 Pages

Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide 2017

Summary

The BRIC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the BRIC pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $159.4 billion in 2016. Russia was the fastest growing country with a CAGR of 19.9% over the 2012-16 period.
- Within the pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of $99.4 billion in 2016. This was followed by India, Russia and Brazil with a value of $29.4, $16.7, and $13.9 billion, respectively.
- China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $155.8 billion in 2021, followed by India, Russia, Brazil with expected values of $59.1, $30.8 and $19.2 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC pharmaceuticals market with five year forecasts
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons to buy

- What was the size of the BRIC pharmaceuticals market by value in 2016?
- What will be the size of the BRIC pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the BRIC pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the BRIC pharmaceuticals market?
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
BRIC Pharmaceuticals
Industry Outlook
Pharmaceuticals in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables
Table 1: BRIC pharmaceuticals industry, revenue($bn), 2012-21
Table 2: BRIC pharmaceuticals industry, revenue($bn), 2012-16
Table 3: BRIC pharmaceuticals industry, revenue($bn), 2016-21
Table 4: Brazil pharmaceuticals market value: $ billion, 201216
Table 5: Brazil pharmaceuticals market geography segmentation: $ billion, 2016
Table 6: Brazil pharmaceuticals market share: % share, by value, 2016
Table 7: Brazil pharmaceuticals market value forecast: $ billion, 201621
Table 8: Brazil size of population (million), 201216
Table 9: Brazil gdp (constant 2005 prices, $ billion), 201216
Table 10: Brazil gdp (current prices, $ billion), 201216
Table 11: Brazil inflation, 201216
Table 12: Brazil consumer price index (absolute), 201216
Table 13: Brazil exchange rate, 201216
Table 14: China pharmaceuticals market value: $ billion, 201216
Table 15: China pharmaceuticals market geography segmentation: $ billion, 2016
Table 16: China pharmaceuticals market share: % share, by value, 2016
Table 17: China pharmaceuticals market value forecast: $ billion, 201621
Table 18: China size of population (million), 201216
Table 19: China gdp (constant 2005 prices, $ billion), 201216
Table 20: China gdp (current prices, $ billion), 201216
Table 21: China inflation, 201216
Table 22: China consumer price index (absolute), 201216
Table 23: China exchange rate, 201216
Table 24: India pharmaceuticals market value: $ billion, 201216
Table 25: India pharmaceuticals market geography segmentation: $ billion, 2016
Table 26: India pharmaceuticals market share: % share, by value, 2016
Table 27: India pharmaceuticals market value forecast: $ billion, 201621
Table 28: India size of population (million), 201216
Table 29: India gdp (constant 2005 prices, $ billion), 201216
Table 30: India gdp (current prices, $ billion), 201216
Table 31: India inflation, 201216
Table 32: India consumer price index (absolute), 201216
Table 33: India exchange rate, 201216
Table 34: Russia pharmaceuticals market value: $ billion, 201216
Table 35: Russia pharmaceuticals market geography segmentation: $ billion, 2016
Table 36: Russia pharmaceuticals market share: % share, by value, 2016
Table 37: Russia pharmaceuticals market value forecast: $ billion, 201621
Table 38: Russia size of population (million), 201216
Table 39: Russia gdp (constant 2005 prices, $ billion), 201216
Table 40: Russia gdp (current prices, $ billion), 201216
Table 41: Russia inflation, 201216
Table 42: Russia consumer price index (absolute), 201216
Table 43: Russia exchange rate, 201216
Table 44: Ach Laboratrios Farmacuticos S.A.: key facts
Table 45: EMS SA: key facts
Table 46: Sanofi SA: key facts
Table 47: Sanofi SA: key financials ($)
Table 48: Sanofi SA: key financials ()
Table 49: Sanofi SA: key financial ratios
Table 50: Guangzhou Pharmaceutical Holdings Limited: key facts
Table 51: Shanghai Pharmaceuticals Holding Co Ltd: key facts
Table 52: Shanghai Pharmaceuticals Holding Co Ltd: key financials ($)
Table 53: Shanghai Pharmaceuticals Holding Co Ltd: key financials (CNY)
Table 54: Shanghai Pharmaceuticals Holding Co Ltd: key financial ratios
Table 55: Yangtze River Pharmaceutical Group: key facts
Table 56: Yunnan Baiyao Group Co., Ltd.: key facts
Table 57: Yunnan Baiyao Group Co., Ltd.: key financials ($)
Table 58: Yunnan Baiyao Group Co., Ltd.: key financials (CNY)
Table 59: Yunnan Baiyao Group Co., Ltd.: key financial ratios
Table 60: Aurobindo Pharma Limited: key facts
Table 61: Aurobindo Pharma Limited: key financials ($)
Table 62: Aurobindo Pharma Limited: key financials (Rs.)
Table 63: Aurobindo Pharma Limited: key financial ratios
Table 64: Lupin Limited: key facts
Table 65: Lupin Limited: key financials ($)
Table 66: Lupin Limited: key financials (Rs.)
Table 67: Lupin Limited: key financial ratios
Table 68: Dr. Reddy's Laboratories Limited: key facts
Table 69: Dr. Reddy's Laboratories Limited: key financials ($)
Table 70: Dr. Reddy's Laboratories Limited: key financials (Rs.)
Table 71: Dr. Reddy's Laboratories Limited: key financial ratios
Table 72: Sun Pharmaceutical Industries Ltd.: key facts
Table 73: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 74: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 75: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 76: Bayer AG: key facts
Table 77: Bayer AG: key financials ($)
Table 78: Bayer AG: key financials ()
Table 79: Bayer AG: key financial ratios
Table 80: Novartis AG: key facts
Table 81: Novartis AG: key financials ($)
Table 82: Novartis AG: key financial ratios
Table 83: Les Laboratoires Servier: key facts

List of Figures
Figure 1: BRIC pharmaceuticals industry, revenue($bn), 2012-21
Figure 2: BRIC pharmaceuticals industry, revenue($bn), 2012-16
Figure 3: BRIC pharmaceuticals industry, revenue($bn), 2016-21
Figure 4: Brazil pharmaceuticals market value: $ billion, 201216
Figure 5: Brazil pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 6: Brazil pharmaceuticals market share: % share, by value, 2016
Figure 7: Brazil pharmaceuticals market value forecast: $ billion, 201621
Figure 8: Forces driving competition in the pharmaceuticals market in Brazil, 2016
Figure 9: Drivers of buyer power in the pharmaceuticals market in Brazil, 2016
Figure 10: Drivers of supplier power in the pharmaceuticals market in Brazil, 2016
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2016
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2016
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2016
Figure 14: China pharmaceuticals market value: $ billion, 201216
Figure 15: China pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 16: China pharmaceuticals market share: % share, by value, 2016
Figure 17: China pharmaceuticals market value forecast: $ billion, 201621
Figure 18: Forces driving competition in the pharmaceuticals market in China, 2016
Figure 19: Drivers of buyer power in the pharmaceuticals market in China, 2016
Figure 20: Drivers of supplier power in the pharmaceuticals market in China, 2016
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2016
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2016
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in China, 2016
Figure 24: India pharmaceuticals market value: $ billion, 201216
Figure 25: India pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 26: India pharmaceuticals market share: % share, by value, 2016
Figure 27: India pharmaceuticals market value forecast: $ billion, 201621
Figure 28: Forces driving competition in the pharmaceuticals market in India, 2016
Figure 29: Drivers of buyer power in the pharmaceuticals market in India, 2016
Figure 30: Drivers of supplier power in the pharmaceuticals market in India, 2016
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2016
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2016
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in India, 2016
Figure 34: Russia pharmaceuticals market value: $ billion, 201216
Figure 35: Russia pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 36: Russia pharmaceuticals market share: % share, by value, 2016
Figure 37: Russia pharmaceuticals market value forecast: $ billion, 201621
Figure 38: Forces driving competition in the pharmaceuticals market in Russia, 2016
Figure 39: Drivers of buyer power in the pharmaceuticals market in Russia, 2016
Figure 40: Drivers of supplier power in the pharmaceuticals market in Russia, 2016
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2016
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2016
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2016
Figure 44: Sanofi SA: revenues & profitability
Figure 45: Sanofi SA: assets & liabilities
Figure 46: Shanghai Pharmaceuticals Holding Co Ltd: revenues & profitability
Figure 47: Shanghai Pharmaceuticals Holding Co Ltd: assets & liabilities
Figure 48: Yunnan Baiyao Group Co., Ltd.: revenues & profitability
Figure 49: Yunnan Baiyao Group Co., Ltd.: assets & liabilities
Figure 50: Aurobindo Pharma Limited: revenues & profitability
Figure 51: Aurobindo Pharma Limited: assets & liabilities
Figure 52: Lupin Limited: revenues & profitability
Figure 53: Lupin Limited: assets & liabilities
Figure 54: Dr. Reddy's Laboratories Limited: revenues & profitability
Figure 55: Dr. Reddy's Laboratories Limited: assets & liabilities
Figure 56: Sun Pharmaceutical Industries Ltd.: revenues & profitability
Figure 57: Sun Pharmaceutical Industries Ltd.: assets & liabilities
Figure 58: Bayer AG: revenues & profitability
Figure 59: Bayer AG: assets & liabilities
Figure 60: Novartis AG: revenues & profitability
Figure 61: Novartis AG: assets & liabilities

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *